Nurulimab
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma[1].
Product Specifications
CAS Number
[2168561-20-2]
Product Name Alternative
BCD-145
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nurulimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Nurulimab]
Molecular Weight
(143.78 kDa)
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 34, No. 1, 2020.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
134280-HRP 100 µL
TCEAL1 (Transcription Elongation Factor A Protein-like 1, TCEA-like Protein 1, pp21, Nuclear Phosphoprotein p21/SIIR, SIIR, Transcription Elongation Factor S-II Protein-like 1) (HRP)
Ask
View Details 
123626-FITC 100 µL
ASNA1 (ATPase ASNA1, Arsenical Pump-driving ATPase, Arsenite-stimulated ATPase, Transmembrane Domain Recognition Complex 40kD ATPase Subunit, hARSA-I, hASNA-I, ARSA, TRC40) (FITC)
Ask
View Details 
